Arno Therapeutics Inc (ARNI) financial statements (2022 and earlier)

Company profile

Business Address 200 ROUTE 31 NORTH
FLEMINGTON, NJ 08822
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,1249372,684671232,3684,935
Cash and cash equivalents2,1249372,684671232,3684,935
Other undisclosed current assets203131209261251170171
Total current assets:2,3271,0692,8933283742,5385,105
Noncurrent Assets
Property, plant and equipment18202123252729
Deposits noncurrent assets10101010101010
Total noncurrent assets:28303234353739
TOTAL ASSETS:2,3561,0992,9243614102,5765,144
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,0657097881,0101,1751,089572
Accounts payable1,0657097881,0101,1751,089572
Debt4444443
Deferred revenue and credits2222110
Other undisclosed current liabilities4561,0695023,2159831,2911,344
Total current liabilities:1,5271,7841,2964,2312,1642,3851,919
Noncurrent Liabilities
Long-term debt and lease obligation1234567
Capital lease obligations1234567
Liabilities, other than long-term debt6,5424,5315,6494,7513,4855,6856,229
Derivative instruments and hedges, liabilities6,5424,5315,6494,7513,4855,6856,229
Total noncurrent liabilities:6,5424,5335,6524,7553,4915,6916,236
Total liabilities:8,0706,3176,9488,9855,6548,0758,156
Stockholders' equity
Stockholders' equity attributable to parent, including:(5,714)(5,219)(4,023)(8,624)(5,245)(5,500)(3,012)
Common stock8885555
Common stock, value, subscriptions150      
Additional paid in capital97,12393,92092,97384,66584,05083,11682,159
Accumulated deficit(102,995)(99,146)(97,004)(93,295)(89,300)(88,621) 
Other undisclosed stockholders' equity attributable to parent      (85,176)
Total stockholders' equity:(5,714)(5,219)(4,023)(8,624)(5,245)(5,500)(3,012)
TOTAL LIABILITIES AND EQUITY:2,3561,0992,9243614102,5765,144

Income statement (P&L) ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Operating expenses(2,231)(3,311)(2,825)(2,696)(2,875)(3,979)(3,862)
Operating loss:(2,231)(3,311)(2,825)(2,696)(2,875)(3,979)(3,862)
Nonoperating income (expense)(1,618)1,168(884)(1,299)2,195534474
Other nonoperating income (expense)(1,618)1,167(871)(1,272)2,195532470
Interest and debt expense(0)(0)(15)(27)(0)(0)(0)
Net loss:(3,849)(2,143)(3,723)(4,022)(680)(3,445)(3,389)
Other undisclosed net income attributable to parent001527000
Net loss available to common stockholders, diluted:(3,849)(2,142)(3,709)(3,995)(679)(3,445)(3,389)

Comprehensive Income ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Net loss:(3,849)(2,143)(3,723)(4,022)(680)(3,445)(3,389)
Comprehensive loss, net of tax, attributable to parent:(3,849)(2,143)(3,723)(4,022)(680)(3,445)(3,389)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: